If you've spent any time in longevity circles, you've heard it: "Rapamycin doesn't get into the brain. It's not even in the spinal fluid." A new narrative review in the Journal of Alzheimer's Disease argues that this popular claim rests on a bad proxy, and that the evidence points the other way.
The catch: nobody has yet measured the parent drug directly in intact human brain tissue at the low doses longevity users take. More on that below.
Source: Melin JM, Young NA, Camardo J. "Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus)." J Alzheimers Dis, 2026. PubMed | DOI
The "CSF misconception"
Rapamycin (sirolimus) is a potent inhibitor of mTORC1, a growth and nutrient-sensing pathway tied to aging biology. It is a leading candidate for age-related neurodegenerative disease. Yet many researchers assume it can't enter the brain, because it generally isn't detectable in cerebrospinal fluid (CSF).
The authors call this the "CSF misconception." Their argument is that failing to find a drug in CSF is not the same as failing to reach brain tissue.
Why rapamycin vanishes from CSF anyway
The review identifies four pharmacological reasons rapamycin is hard to detect in CSF, none of which means it's locked out of the brain:
- High lipophilicity. The drug is fat-loving and can be sequestered in brain parenchyma (the tissue itself) rather than floating in fluid.
- Extreme red-cell and protein binding. Very little drug stays free and measurable.
- P-glycoprotein efflux at the blood-CSF barrier. This pump pushes the drug back out at that specific interface.
- Assay insensitivity. Standard assays may simply be too insensitive to pick up the low concentrations present.
The conclusion: CSF concentration is "a flawed proxy" for how much rapamycin reaches the central nervous system.
The human evidence
The strongest direct data come from glioblastoma. Tissue sampling in these patients detected rapamycin in brain at concentrations sufficient to inhibit mTORC1. That is real human brain tissue, though it is tumor-affected tissue, not a healthy aging brain.
The review then lines up functional evidence that the drug is doing something in the brain:
- Tuberous sclerosis complex (TSC): tumor regression and seizure control.
- Alzheimer's disease: preservation of cerebral metabolism on PET imaging.
- APOE4 carriers: increased cerebral blood flow.
- Depression: prolonged antidepressant response.
The authors describe these effects as "incontrovertible activity in the brain." That is their interpretation. These are different populations, doses, and study designs, and the review is narrative rather than a systematic meta-analysis. Readers should treat the findings as converging clues, not a single proof.
The animal evidence (mice)
In mice, LC-MS/MS (a highly sensitive mass-spectrometry method) confirmed dose-dependent accumulation of rapamycin in brain. Rapamycin also modulated mTORC1 signaling, autophagy, and synaptic, epigenetic, and inflammatory pathways. This is preclinical work. Mouse brain data don't automatically translate to humans taking intermittent oral dosing.
The gap the authors admit
The review is candid about the central hole: direct measurement of parent drug in intact human brain parenchyma at therapeutic doses is lacking. The glioblastoma tissue data are the closest, but they involve a diseased brain and a specific clinical setting. So the honest summary is not "proven to reach healthy brains at longevity doses." It is "the claim that it can't reach the brain is poorly supported."
What this means for longevity users
The myth: "No CSF signal means no brain effect." The better reading: CSF is the wrong place to look. Tissue data, imaging, and clinical effects suggest rapamycin is active in the CNS.
Practical takeaways
- Dose and timing: The review does not establish a dose or schedule for brain protection or longevity, and neither can this article. Any off-label regimen should be set with a physician who can monitor you.
- Who this is relevant to: People following Alzheimer's and healthy-brain-aging research, and those weighing whether the "brain penetration" objection should rule rapamycin out. On this evidence, it shouldn't.
- Who should be cautious or skip it: Rapamycin is a prescription immunosuppressant. People with active infections, those who are pregnant or trying to conceive, anyone with poor wound healing or surgery planned, and anyone with significant lipid or glucose issues should talk with a clinician first. Known side effects include mouth sores and metabolic changes. These are general drug-safety points, not findings of this review.
- Don't self-treat: The review supports a mechanism, not a proven prevention strategy. Whether rapamycin prevents dementia in healthy people is still untested.
What researchers should do next
The authors recommend that Alzheimer's disease and related dementias (ADRD) trials stop leaning on CSF drug levels. Instead they should track:
- Surrogate markers of mTORC1 inhibition
- Functional neuroimaging
- Clinical outcomes
- ADRD fluid biomarkers
These pharmacodynamic measurements, they argue, are essential for designing and interpreting prevention trials in the aging brain.
Bottom line
"Rapamycin can't reach the brain" looks like an artifact of where people have been measuring. The evidence is suggestive and converging, but not yet definitive for healthy humans at longevity doses. Until direct brain measurements and prevention trials arrive, treat rapamycin as a promising, prescription-only, still-experimental option for the brain.
Full review: PubMed 42852863 | DOI: 10.1177/13872877261495936. This article is for information only and is not medical advice.